Plain-English translation of NCT05727163 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether delivering chemotherapy drugs directly to the liver through a catheter (a thin tube) works better than delivering them into the bloodstream the traditional way. The trial combines FOLFOX chemotherapy with another drug called , with or without (a medication that stops blood vessel growth to tumors). Researchers want to see if this new delivery method helps shrink liver tumors better and makes surgery possible for patients whose cancer was initially too advanced to operate on.
For people with colorectal cancer that has spread to the liver but cannot be surgically removed, current chemotherapy treatments have limited success. Doctors believe that delivering the medication directly to the liver through an artery might reach cancer cells more effectively and give more patients the chance to have surgery to remove their remaining tumors.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive chemotherapy either through a catheter placed in the artery leading to your liver or through a traditional IV line in your arm. You will receive treatment every 14 days for up to 12 cycles (about 6 months total). Your medical team will monitor you closely with blood tests and imaging scans to see how well the treatment is working, and if your tumors shrink enough, you may become eligible for surgery to remove them. You will be followed for side effects and overall health throughout treatment and after.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China